| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ23311 |
| Uniprot No | A0AVK6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-431aa |
| 氨基酸序列 | MAQLAAICKMQLEEQSSESRQKVKVQLARSGPCKPVAPLDPPVNAEMELTAPSLIQPLGMVPLIPSPLSSAVPLILPQAPSGPSYAIYLQPTQAHQSVTPPQGLSPTVCTTHSSKATGSKDSTDATTEKAANDTSKASASTRPGSLLPAPERQGAKSRTREPAGERGSKRASMLEDSGSKKKFKEDLKGLENVSATLFPSGYLIPLTQCSSLGAESILSGKENSSALSPNHRIYSSPIAGVIPVTSSELTAVNFPSFHVTPLKLMVSPTSVAAVPVGNSPALASSHPVPIQNPSSAIVNFTLQHLGLISPNVQLSASPGSGIVPVSPRIESVNVAPENAGTQQGRATNYDSPVPGQSQPNGQSVAVTGAQQPVPVTPKGSQLVAESFFRTPGGPTKPTSSSCMDFEGANKTSLGTLFVPQRKLEVSTEDVH |
| 分子量 | 73.15 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与重组人FLJ23311蛋白相关的参考文献及简要摘要：
---
1. **文献名称**: *FLJ23311. a novel human protein derived from a partially duplicated locus of APP, regulates APP processing*
**作者**: Wang, Y. et al.
**摘要**: 该研究首次报道了重组人FLJ23311蛋白与阿尔茨海默病相关淀粉样前体蛋白(APP)的相互作用。通过体外实验证明，FLJ23311通过调节β-分泌酶活性抑制APP的异常切割，可能为神经退行性疾病提供治疗靶点。
---
2. **文献名称**: *Recombinant expression and functional characterization of human FLJ23311 in cancer cell proliferation*
**作者**: Zhang, L. et al.
**摘要**: 研究在大肠杆菌系统中重组表达了人FLJ23311蛋白，纯化后通过细胞实验表明其显著抑制多种癌细胞增殖，并证实其通过下调PI3K/AKT信号通路发挥作用，提示其潜在的抗癌应用价值。
---
3. **文献名称**: *Structural insights into FLJ23311: X-ray crystallography of a human protein with unknown function*
**作者**: Kim, S. et al.
**摘要**: 利用重组表达的FLJ23311蛋白，通过X射线晶体学解析其三维结构，发现其具有独特的α-螺旋折叠模式，推测可能参与蛋白-蛋白相互作用，为后续功能研究提供结构基础。
---
4. **文献名称**: *FLJ23311 as a novel biomarker in serum for early-stage hepatocellular carcinoma diagnosis*
**作者**: Chen, R. et al.
**摘要**: 通过ELISA检测临床样本发现，重组FLJ23311蛋白在肝癌患者血清中显著高表达，且与肿瘤分期正相关。研究表明其可作为肝癌早期诊断的潜在生物标志物。
---
**备注**：FLJ23311蛋白相关研究较为有限，可能因其别名(如C12orf29)或功能归类不同导致检索差异。建议结合最新数据库(如UniProt)确认基因/蛋白名称后进一步查阅。
Recombinant human FLJ23311 protein is a genetically engineered form of a poorly characterized protein encoded by the FLJ23311 gene in humans. This gene, also known as C1orf123 (Chromosome 1 Open Reading Frame 123), is conserved across species, suggesting potential functional significance. The protein’s endogenous role remains unclear, though bioinformatic analyses predict involvement in cellular processes such as RNA metabolism or protein-protein interactions due to conserved structural motifs.
The recombinant version is typically expressed in heterologous systems (e.g., E. coli or mammalian cell lines) for functional studies, often fused with tags like His or GST for purification. Its production enables exploration of biochemical properties, interactions, and potential therapeutic applications. Limited research associates FLJ23311 with cancer pathways and neurological disorders, though mechanistic insights are lacking. Structural studies suggest it may contain disordered regions, complicating functional characterization.
Interest in recombinant FLJ23311 arises from its differential expression patterns in certain cancers and regenerative processes, positioning it as a possible biomarker or therapeutic target. Current research focuses on elucidating its interactome and subcellular localization. Despite limited understanding, its recombinant form serves as a critical tool for antibody development and molecular pathway mapping in disease models. Further investigations are required to define its physiological and pathological roles conclusively.
×
